Merck KGaA completes enrollment in late-stage trial for Parkinson’s disease drug
DARMSTADT, Germany — Merck KGaA has finished enrolling patients in a late-stage clinical study of a drug for Parkinson’s disease, the German drug maker said.
Merck KGaA, which is a separate company from U.S.-based Merck & Co. and operates in the United States under the name EMD, said 549 patients with mid- to late-stage Parkinson’s had enrolled in the phase-3 "SETTLE" study of safinamide. The study is designed to evaluate the drug’s safety and efficacy as an add-on therapy to levodopa, a common treatment for Parkinson’s.
The study is part of a broader program for the drug and will last for six months.
Stiefel seeks FDA approval for tazarotene foam
RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline company Stiefel announced it is seeking approval for a facial acne treatment in patients ages 12 years and older.
Stiefel said it has submitted a new drug application to the Food and Drug Administration for tazarotene foam. Tazarotene foam is subject to evaluation and approval by the regulatory authorities before it can be made available to physicians for prescribing to their appropriate patients, Stiefel said.
Last month, Stiefel brought to market its Revaleskin-branded anti-aging treatment, Revaleskin Illuminesse Brightening Complex.
NASN, Sanofi Pasteur team up to raise awareness of meningitis
NEW YORK — Meningococcal meningitis is rare but can kill preteens and teenagers in as little as a day. Yet many kids still engage in behaviors that put them at risk of contracting the disease despite not being vaccinated.
The National Association of School Nurses, working with Sanofi Pasteur, the vaccines division of French drug maker Sanofi, released results of a survey conducted as part of the Voices of Meningitis back-to-school vaccination awareness initiative. The initiative has enlisted as a celebrity spokeswoman singer and Disney Channel star Tiffany Thornton, who nearly died from meningococcal disease as a teenager.
"Most of our preteens and teens are unprotected against meningitis and at the same time are regularly engaging in behaviors that may put them at risk," NASN president Linda Davis-Alldritt said. "While we may not be able to prevent our teens from engaging in these activities, we can take steps to help protect them by making sure they are immunized against meningitis."
According to survey results, almost half of all preteens and teenagers are unvaccinated against meningococcal disease, and there is low awareness of the disease among kids and parents.
In addition, more than 80% of kids ages 11 to 17 years reported engaging in everyday activities that put them at risk, including sharing drinking glasses and water bottles, not getting enough sleep, living in places like dormitories and kissing.